share_log

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Barclays PLC

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Barclays PLC

巴克莱集团收购了Anavex Life Sciences Corp.(纳斯达克股票代码:AVXL)的股票
Defense World ·  2023/02/04 05:32

Barclays PLC raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating) by 1,792.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,290 shares of the biotechnology company's stock after acquiring an additional 179,290 shares during the period. Barclays PLC owned 0.24% of Anavex Life Sciences worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

根据巴克莱集团向美国证券交易委员会(SEC)提交的最新13F表文件,巴克莱集团在第三季度将其在Anavex Life Sciences Corp.(纳斯达克股票代码:AVXL — 获取评级)的股份提高了1,792.9%。该机构投资者在此期间又收购了179,290股生物技术公司的股票后,拥有该生物技术公司的189,290股股票。截至最近向美国证券交易委员会(SEC)提交文件时,巴克莱集团拥有Anavex Life Sciences0.24%的股份,价值19.53万美元。

Several other large investors also recently bought and sold shares of AVXL. Lazard Asset Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $26,000. SeaCrest Wealth Management LLC acquired a new position in Anavex Life Sciences in the second quarter valued at $44,000. Quantbot Technologies LP acquired a new position in Anavex Life Sciences in the second quarter valued at $64,000. Janney Montgomery Scott LLC acquired a new position in Anavex Life Sciences in the third quarter valued at $108,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Anavex Life Sciences during the first quarter worth about $136,000. Institutional investors and hedge funds own 31.22% of the company's stock.

其他几位大型投资者最近也买入和卖出了AVXL的股票。拉扎德资产管理有限责任公司在第二季度收购了Anavex Life Sciences的新职位,价值26,000美元。SeaCrest Wealth Management LLC在第二季度收购了Anavex Life Sciences的新职位,价值44,000美元。Quantbot Technologies LP在第二季度收购了Anavex Life Sciences的新职位,价值64,000美元。詹尼·蒙哥马利·斯科特有限责任公司在第三季度收购了Anavex Life Sciences的新职位,价值10.8万美元。最后,Atria Wealth Solutions Inc.在第一季度收购了Anavex Life Sciences股票的新股份,价值约13.6万美元。机构投资者和对冲基金拥有该公司31.22%的股票。

Get
获取
Anavex Life Sciences
Anavex 生命科学
alerts:
警报:

Anavex Life Sciences Stock Down 1.0 %

Anavex 生命科学股价下跌 1.0%

Shares of NASDAQ:AVXL opened at $11.26 on Friday. The company has a market cap of $878.62 million, a P/E ratio of -18.16 and a beta of 0.77. Anavex Life Sciences Corp. has a 52 week low of $7.13 and a 52 week high of $15.24. The company has a 50-day moving average price of $9.60 and a 200 day moving average price of $10.46.

纳斯达克股票代码:AVXL的股价周五开盘价为11.26美元。该公司的市值为8.7862亿美元,市盈率为-18.16,beta为0.77。Anavex Life Sciences Corp. 创下52周低点7.13美元,创下52周高点15.24美元。该公司的50天移动平均价格为9.60美元,200天移动平均线价格为10.46美元。

Anavex Life Sciences (NASDAQ:AVXL – Get Rating) last announced its quarterly earnings data on Monday, November 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). Analysts expect that Anavex Life Sciences Corp. will post -0.81 EPS for the current year.
Anavex Life Sciences(纳斯达克股票代码:AVXL — 获取评级)上次公布季度收益数据是在11月28日星期一。这家生物技术公司公布了本季度每股收益(0.18美元),比分析师普遍预期的(0.16美元)低了(0.02美元)。分析师预计,Anavex Life Sciences Corp. 今年每股收益将为-0.81。

Analysts Set New Price Targets

分析师设定了新的价格目标

Several brokerages have recently weighed in on AVXL. StockNews.com began coverage on shares of Anavex Life Sciences in a research note on Wednesday, October 12th. They set a "sell" rating for the company. Jonestrading increased their target price on shares of Anavex Life Sciences from $40.00 to $80.00 in a research note on Friday, December 2nd. HC Wainwright increased their target price on shares of Anavex Life Sciences from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald downgraded shares of Anavex Life Sciences from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $16.00 to $11.00 in a research note on Tuesday, December 6th.

最近有几家经纪公司对AVXL进行了权衡。StockNews.com在10月12日星期三的一份研究报告中开始报道Anavex Life Sciences的股票。他们为公司设定了 “卖出” 评级。Jonestrading在12月2日星期五的一份研究报告中将Anavex Life Sciences股票的目标价格从40.00美元上调至80.00美元。HC Wainwright在1月3日星期二的一份研究报告中将Anavex Life Sciences股票的目标价格从42.00美元上调至50.00美元,并将该股评为 “买入”。最后,坎托·菲茨杰拉德在12月6日星期二的一份研究报告中将Anavex Life Sciences的股票评级从 “增持” 下调至 “中性” 评级,并将该股的目标价格从16.00美元下调至11.00美元。

About Anavex Life Sciences

关于 Anavex 生命科学

(Get Rating)

(获取评分)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome.

Anavex Life Sciences Corp. 是一家临床阶段的生物制药公司,从事治疗神经退行性和神经发育疾病的不同疗法的开发。其主要化合物 ANAVEX2-73 正在开发中,用于治疗阿尔茨海默氏症和帕金森氏病以及包括雷特综合征在内的中枢神经系统疾病。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Anavex Life Sciences (AVXL)
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • Insiders And Institutions Buy Wolverine Worldwide
  • 免费获取 StockNews.com 关于 Anavex Life Sciences (AVXL) 的研究报告
  • 细价股值得吗?你应该投资细价股吗?
  • Zimmer Biomet的收益超过预期,增长可能会被定价
  • 人工智能软件制造商 EPAM 拥有最大的科技板块涨势
  • 在收益大幅下滑之后,福特股票将向前发展
  • 内部人士和机构在全球范围内收购金刚狼

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Rating).

想看看还有哪些对冲基金持有 AVXL 吗? 访问Holdingschannel.com,获取Anavex Life Sciences Corp.(纳斯达克股票代码:AVXL — 获取评级)的最新13F文件和内幕交易。

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Anavex 生命科学日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Anavex Life Sciences及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发